Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
As FDA increases the asking price, a survey by non-profit finds companies would expect to invest an average of $100 million to obtain a voucher, but responders gave a wide range of potential amounts.
You may also be interested in...
Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization
Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.
Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.